CSIMarket Company Name, Ticker, Suppliers, else..


Halozyme Therapeutics Inc   (HALO)
Other Ticker:  
 

Halozyme Therapeutics Inc

HALO's Fundamental analysis



Looking into Halozyme Therapeutics Inc growth rates, revenue grew by 34.28 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 527

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.29 %

Halozyme Therapeutics Inc 's net income grew by 67.42 % in III. Quarter 2024 year on year, above company average,

• More on HALO's Growth


Halozyme Therapeutics Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Halozyme Therapeutics Inc PEG ratio is at 0.26 Halozyme Therapeutics Inc realized cash reduction of $ -0.92 per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
15.76
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 6.56.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.


• More on HALO's Valuation
 
 Total Debt (Millions $) 1,504
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 314,631
 Net Income/Employee (TTM) $ 130,344
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) -2.95

Halozyme Therapeutics Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Halozyme Therapeutics Inc PEG ratio is at 0.26 Halozyme Therapeutics Inc realized cash outflow of $ -0.92per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
15.76
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 6.56.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.

Halozyme Therapeutics Inc Price to Book Ratio is at 13.74 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01

• More on HALO's Valuation

•  Market Capitalization (Millions $) 6,219
•  Shares Outstanding (Millions) 130
•  Employees 3,011
•  Revenues (TTM) (Millions $) 947
•  Net Income (TTM) (Millions $) 392
•  Cash Flow (TTM) (Millions $) -120
•  Capital Exp. (TTM) (Millions $) -10
•  Total Debt (Millions $) 1,504
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 314,631
•  Net Income/Employee(TTM) $ 130,344
•  Receivable Turnover Ratio (TTM) -
•  Tangible Book Value (Per Share $) -2.95

•  Market Capitalization (Millions $) 6,219
•  Shares Outstanding (Millions) 130
•  Employees 3,011
•  Revenues (TTM) (Millions $) 947
•  Net Income (TTM) (Millions $) 392
•  Cash Flow (TTM) (Millions $) -120
•  Capital Exp. (TTM) (Millions $) -10


    HALO's Profitability Comparisons
Halozyme Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 56.26 % from 50.67 % in II. Quarter.

Halozyme Therapeutics Inc net profit margin of 47.23 % is currently ranking no. 3 in Biotechnology & Pharmaceuticals industry, ranking no. 14 in Healthcare sector and number 146 in S&P 500.


Profitability by Segment
Total 47.23 %



  Ratio
•   Capital Ratio (MRQ) 10.36
•  Total Debt to Equity (MRQ) 3.32
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.51
•  Inventory Turnover Ratio (TTM) 1.16



Halozyme Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 56.26 % from 50.67 % in II. Quarter.

Halozyme Therapeutics Inc net profit margin of 47.23 % is currently ranking no. 3 in Biotechnology & Pharmaceuticals industry, ranking no. 14 in Healthcare sector and number 146 in S&P 500.

• More on HALO's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com